발작이 발생하기 쉬운 뇌 영역을 식별하기 위한 동시 뇌파검사(Electroencephalography and Magnetoencephalography)

Executive Industry Relevance

Simultaneous EEG and MEG acquisition with advanced detection of interictal epileptiform discharges (IEDs) and high-frequency oscillations (HFOs) enables precise localization of seizure-prone brain regions. This workflow enhances predictive confidence in neurobiological target identification and supports mechanistic de-risking in CNS drug discovery. Integrating quantitative neuroimaging biomarkers at early discovery inflection points informs portfolio triage and translational continuity.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of neuronal network dysfunction through detection of IEDs and HFOs.
• Supports functional target validation by mapping seizure-prone regions with high spatial precision.
• Facilitates mechanistic de-risking by distinguishing true neuronal signals from artifacts using peripheral recordings.
• Improves predictive confidence for CNS target selection and prioritization.

Screening & Assay Development

• Provides validated neurophysiological readouts for downstream compound screening workflows.
• Standardizes detection thresholds for IEDs and HFOs, supporting reproducibility across studies.
• Enables quantitative assessment of neuronal activity for assay development and optimization.
• Prepares robust biological systems for reliable evaluation of candidate interventions.

Translational & Preclinical Research

• Aligns neurophysiological biomarkers with disease-relevant endpoints for translational research.
• Ensures continuity from early discovery through preclinical validation by localizing functional brain regions.
• Supports risk-adjusted advancement decisions based on quantitative mapping of seizure-prone zones.
• Provides mechanistic insights that inform preclinical model selection and validation.

Pipeline & Workflow Integration

This method integrates into the discovery continuum from early target validation through preclinical research, providing quantitative neuroimaging outputs for decision-making.

• Discovery Biology: Supports hypothesis testing and pathway clarification by mapping abnormal neuronal activity.
• Screening: Delivers reproducible, quantitative readouts of IEDs and HFOs for assay readiness.
• Analytics: Generates 3D brain maps and statistical outputs for cross-condition comparison.
• Translational Research: Aligns neurophysiological biomarkers with preclinical endpoints for disease relevance.
• Enterprise Reuse: Establishes a reusable workflow for CNS biomarker discovery and validation.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in CNS target validation.
• Operational Value: Standardizes neuroimaging protocols and ensures reproducibility across studies.
• Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio management.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of CNS programs.

Implementation Considerations

• Requires expertise in EEG, MEG, and advanced neuroimaging analysis.
• Demands access to high-fidelity instrumentation and computational infrastructure for data processing.
• Necessitates cross-team standardization of detection algorithms and artifact exclusion protocols.
• Adaptation may be needed for different patient populations or neurological models.
• Artifact exclusion and thresholding must be rigorously validated to ensure data integrity.

Biopharma FAQs